Latest Breaking News On - Investorsjason kantor - Page 1 : comparemela.com

Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoSan franciscoGwennm hansenInvestorsjason kantorGen degradersArthurt sandsElizabeth wolffeAmerican association for cancer researchNurix therapeutics incAmerican associationCancer researchMajor symposiumMolecular gluesNext gen degradersEarly preclinical advances

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics to Participate in Upcoming Investor Conferences
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesElizabeth wolffeHans van houteArthurt sandsJason kantorInvestorsjason kantorVirtual targeted oncology forum firesideNurix therapeutics incTargeted oncology forum firesideSandler spring biopharma symposiumCasitasb lineageWheelhouse life scienceNurix therapeutics